What the FDA labels say about taking them together
Dexlansoprazole and mycophenolate mofetil
Dexlansoprazole's FDA label of February 17, 2025 names mycophenolate mofetil in its drug interactions section; mycophenolate mofetil's label does not name dexlansoprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The dexlansoprazole label: “Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.”
Check it at the source: the dexlansoprazole FDA label on DailyMed (effective February 17, 2025, Takeda Pharmaceuticals America, Inc.); the mycophenolate mofetil FDA label on DailyMed (effective August 5, 2026, Genentech, Inc.).
What does the dexlansoprazole label say about mycophenolate mofetil?
Dexlansoprazole label, drug interactionsClinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Mycophenolate mofetil (MMF): Coadministration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. …
Source: FDA drug label (Dexilant), Takeda Pharmaceuticals America, Inc., effective February 17, 2025 (SPL set 9819f033-3bbe-442e-8e92-45fec77b237d), via openFDA; the full label on DailyMed
What does the mycophenolate mofetil label say about dexlansoprazole?
Mycophenolate mofetil's label does not name dexlansoprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Mycophenolate mofetil label, drug interactionsDRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce CELLCEPT efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. ( 7.1 ) CELLCEPT may reduce effectiveness of oral contraceptives.
Mycophenolate mofetil label, drug interactionsProton Pump Inhibitors (PPIs) Clinical Impact Concomitant use with PPIs decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ], which may reduce CELLCEPT efficacy.
Source: FDA drug label (CellCept), NDA050722 (Roche Palo), as published by Genentech, Inc., effective August 5, 2026 (SPL set 37241e87-4af4-4dc3-a1aa-ea6f20d8dc40), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dexlansoprazole | Mycophenolate mofetil | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Organ transplant rejection |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $3.71 per capsule 60 mg capsule | $0.138 per capsule 250 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once